UCB at neutral by Merrill

Merrill Lynch analyst Erica Whittaker gave UCB a neutral rating after the company's research and development day and on news that Sanofi will market Xyzal antihistamine in the United States following approval potentially in mid-2007. And while UCB said its second-generation Keppra compound brivaracetam failed in neuropathic pain, the phase 2 epilepsy data were very promising. The company also revealed its new self-injectable device for Cimzia. Shares of the Brussels, Belgium-based biopharmaceutical company were up €0.14, or 0.29%, at €49.04. (Brussels: UCB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.